Needham & Company LLC Reiterates “Buy” Rating for KalVista Pharmaceuticals (NASDAQ:KALV)
KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report)‘s stock had its “buy” rating reissued by Needham & Company LLC in a note issued to investors on Wednesday,Benzinga reports. They presently have a $28.00 price target on the specialty pharmaceutical company’s stock. Needham & Company LLC’s target price suggests a potential upside of 126.90% from the company’s […]
More Stories
Zacks Research Issues Negative Outlook for Ameren Earnings
Ameren Co. (NYSE:AEE – Free Report) – Equities researchers at Zacks Research lowered their Q1 2025 earnings estimates for shares...
DA Davidson Brokers Decrease Earnings Estimates for OCFC
OceanFirst Financial Corp. (NASDAQ:OCFC – Free Report) – Equities research analysts at DA Davidson cut their FY2025 EPS estimates for...
Q1 EPS Estimate for Allurion Technologies Lowered by Analyst
Allurion Technologies Inc. (NYSE:ALUR – Free Report) – Equities research analysts at Roth Capital dropped their Q1 2025 earnings estimates...
Northland Capmk Forecasts Increased Earnings for Abacus Life
Abacus Life, Inc. (NASDAQ:ABL – Free Report) – Investment analysts at Northland Capmk upped their Q1 2025 EPS estimates for...
Zacks Research Analysts Lift Earnings Estimates for MLM
Martin Marietta Materials, Inc. (NYSE:MLM – Free Report) – Zacks Research upped their Q3 2025 earnings per share (EPS) estimates...
FY2025 EPS Estimates for WNS Boosted by Barrington Research
WNS (Holdings) Limited (NYSE:WNS – Free Report) – Barrington Research raised their FY2025 earnings per share (EPS) estimates for shares...